Theravance Biopharma, Inc. – Or (NASDAQ:TBPH):
Theravance Biopharma and Mylan Report Additional Positive Phase 3 Data for Revefenacin (TD-4208) in Multiple Presentations at 2017 CHEST Annual Meeting.
The company is trading unchanged by % since yesterday’s close of $28.86.
Theravance Biopharma, Inc. (Theravance Biopharma) is a biopharmaceutical company. The Company is involved in creating medicines for patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Business’s pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting. The Business’s commercial product VIBATIV (telavancin) is a once-daily dual-mechanism antibiotic approved in the United States and Europe for certain difficult-to-treat infections. Its Revefenacin (TD-4208) is a long-acting muscarinic antagonist (LAMA) being developed as a nebulized treatment for chronic obstructive pulmonary disease (COPD). The Business’s neprilysin (NEP) inhibitor program is designed to develop selective NEP inhibitors for the treatment of a range of cardiovascular and renal diseases, including acute and chronic heart failure, hypertension and chronic kidney diseases, such as diabetic nephropathy..
Shares of the company are trading at $28.86 quite a bit lower than the 50 day moving average of $32.83 and impressively lower than the 200 day moving average of $35.05. The 50 day moving average moved down $-3.97 and the 200 day average went down by -17.66%.
As of the last earnings report the EPS was $-4.66 and is estimated to be $-4.85 for the current year with 53,829,000 shares now outstanding. Next quarter’s EPS is expected be $-1.19 and the next full year EPS is anticipated to be $-4.21.
Short traders are more bullish on shares of the company lately if you put credence in the decrease in short interest. The company recorded a fall in short interest from September 29, 2017 to October 13, 2017 of -3.18%. Short interest decreased 202,323 over that period. Days to cover decreased -5.0 to 32.0 and the percentage of shorted shares was 0.12% on October 13.
Investment firms have released opinions on the stock of late. Equity analyst Evercore ISI Group added TBPH to its research portfolio giving it an initial rating of “Outperform”.